Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study

Trial Profile

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ASPIRE
  • Most Recent Events

    • 31 Oct 2018 Results assessing levels of residual viremia by an ultrasensitive viral load assay to determine whether dolutegravir and lamivudine presented at the 14th International Congress on Drug Therapy and HIV Infection.
    • 31 Aug 2018 Biomarkers information updated
    • 27 Jul 2018 Results assessing genital HIV-1 shedding with Dolutegravir plus Lamivudine dual therapy in patients from ASPIRE and ACTG-A5353 studies (n=41) presented at the 22nd International AIDS Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top